Published : 26 Dec 2025
We are living through a data paradox. We have access to more clinical information than at any point in human history, yet the ability to verify that information has never been more fragile. For the pharmaceutical industry, specifically teams working in Health Economics and Outcomes Research (HEOR) and Market Access, this presents a critical operational threat.
The pressure to move faster is immense. With the sheer volume of medical literature doubling every few months, the traditional manual methods of conducting Systematic Literature Reviews (SLRs) are reaching a breaking point.
Speed is useless without provenance. If an algorithm generates a clinical insight but cannot tell you exactly where it came from, it is not evidence. This is the central tension of our time. We must balance the velocity of AI with the rigour of science. The solution lies in a fundamental shift toward traceable AI in healthcare. It is no longer enough just to get the right answer.
To satisfy regulators and payers, you must be able to prove how you arrived at that answer step by step and citation by citation. Evidence traceability is ceasing to be a backend technical detail. It is becoming the frontline of regulatory defence.
To understand why this matters, we must first define what we mean by traceability in a regulated environment. In supply chain logistics, you can track a single vial of a biologic drug from the manufacturing floor to the cold storage facility and finally to the patient's bedside. In evidence generation, evidence traceability must be just as rigorous.
It is the digital thread that connects a final claim in a Global Value Dossier back to the specific sentence in the specific clinical trial PDF from the specific database where it originated. It is the chain of custody for knowledge.
For HTA bodies like NICE in the UK, IQWiG in Germany, and CADTH in Canada, this chain of custody is not optional. It is the currency of trust. Provenance and citation integrity are what separate robust science from anecdotal conjecture.
Consider the risk of data that is not traceable. If an HTA evaluator challenges a specific cost-effectiveness parameter during a submission review and asks where a utility value came from, the response cannot be that an internal AI model suggested it. The response must be a specific citation verified by a human expert.
If that data point cannot be traced instantly, credibility is lost. The risk is not just a delay. It is a rejection. Submissions have stalled simply because reviewers could not replicate the search strategy or verify the extraction logic behind a pivotal claim.
The sudden influx of generic Large Language Models (LLMs) into research workflows has complicated this landscape. Tools like ChatGPT or Claude are linguistic marvels, but they are scientific novices. They were built to predict the next plausible word in a sentence rather than to validate clinical truth.
When teams attempt to use these generalist tools for an AI systematic literature review, they encounter three fatal flaws.
1. Zero Provenance and the Source Problem: You might ask a generic tool to summarise the safety profile of Inhibitor Y. It provides a fluent and convincing paragraph. But it often cannot tell you which studies contributed to that summary. It is an answer without a receipt. In a scientific context, an insight without a source is indistinguishable from a hallucination.
2. The Audit Gap: In a systematic review, every decision to include or exclude a paper must be defensible. Generic tools often act as black boxes that make decisions based on opaque weights that cannot be audited by a human reviewer. You cannot ask the model why it excluded a specific study. This makes complying with PRISMA guidelines impossible.
3. Guideline Mismatch: These tools are unaware of the rigorous standards of PRISMA or GRADE. They prioritise conversational fluency over methodological rigidity. They might gloss over a high risk of bias in a study because the abstract was written confidently. This creates outputs that look good on the surface but fail the stress test of regulatory scrutiny.
This is why generic automation fails. It attempts to replace the researcher. Traceable AI in healthcare, by contrast, empowers the researcher by handling the grunt work while keeping the proof front and centre.
True AI-powered reviews do not just generate text. They generate evidence. When traceability is baked into the architecture of the tool, it changes the role of AI from a writer to a research assistant.
1. Ensuring Reproducibility: Science is built on reproducibility. A traceable system ensures that if you run the same screening criteria today and next year, you get the same result. It logs every decision to include or exclude a record. This creates a permanent record of the search strategy. This is critical for defending the integrity of the review years down the line.
2. Transparency in Synthesis: When AI extracts data for an AI systematic literature review, it must tag the source. This allows human reviewers to validate the synthesis during the grading process to ensure no hallucinated data points enter the model. The AI acts as a highlighter that points the human expert to the relevant section of the text rather than an oracle delivering a verdict from the clouds.
3. Supporting Audit Readiness: The final output is not just a report. It is a database of decisions. This supports audit-ready evidence synthesis, allowing HTA reviewers to peel back the layers of the submission and see the raw evidence underneath. It transforms the submission from a static document into a verified assertion of value.
Pienomial was architected specifically to solve the black box problem by enforcing a glass box approach to evidence. We understand that in life sciences, the how is just as important as the what.
1. Knolens SLR Transparent Screening Trail: Within the Knolens SLR module, every single decision made during the screening process is time-stamped and logged. You can generate a PRISMA flow diagram that is backed by a granular audit trail of every excluded record. If an auditor asks why a specific paper was rejected, the system provides the exact reason and the timestamp of the decision. This is how you solve the problem of how to ensure traceability in AI-generated insights.
2. Full Citation Provenance in Knolens Quest: Unlike generic chat tools, Knolens Quest provides full citation provenance. When it makes a claim or answers a query about a clinical trial, it provides a direct hyperlink to the source text in the original PDF. You don't have to trust the AI. You can click and verify. This verification capability is the difference between a tool that is fun to use and a tool that is safe to use.
3. Centralised Repository via DataNexus: All this data lives in DataNexus, our centralised traceability repository. This ensures that the data point used in your Slide Deck is the exact same data point linked to the same source used in your Global Value Dossier. It prevents the data fragmentation that occurs when teams work in disconnected spreadsheets.
Regulators are catching up to AI, and their expectations are crystallising. The era of blindly trusting the output is over.
1. Credibility with Global Bodies: Agencies like NICE in the UK, CADTH in Canada, IQWiG in Germany, and PBAC in Australia have explicitly updated frameworks to demand transparency in real-world evidence. They scrutinise the process as much as the outcome. With the implementation of the EU Joint Clinical Assessment (JCA), the demand for evidence traceability requirements for HTA submissions is becoming harmonised and stricter. Submissions that rely on opaque methodologies will struggle to pass the validation phase.
2. Reducing Risks During Review Cycles: A fully traceable dossier inoculates you against the most common questions during reimbursement review cycles. If a reviewer challenges a data point, you can instantly produce the source lineage. This agility can save weeks of back-and-forth correspondence and keep the launch timeline on track.
3. Enabling Consistent Evidence: Finally, evidence traceability ensures that your evidence tells the same story across every dossier in every market. It prevents the version control nightmare that often plagues global launches where different affiliates cite different numbers for the same endpoint.
Adopting traceable AI in healthcare is not just a compliance exercise. It is a competitive advantage.
Teams that utilise audit-ready evidence synthesis move with greater confidence. They spend less time double-checking spreadsheets and more time crafting the value story. They can respond to payer objections in real time because they have the data at their fingertips. In a competitive therapeutic area, this speed and confidence can be the difference between a first-cycle approval and a prolonged negotiation.
In modern HEOR and HTA workflows, speed is valuable, but traceability is vital. The industry is moving past the hype of generative AI and embracing verified, audit-ready evidence.
The future belongs to teams that can not only find the insights but also prove them. As the scrutiny on AI in healthcare intensifies, the companies that thrive will be those that have built their evidence generation engines on a foundation of transparency.
If your team is ready to stop trusting the algorithm and start verifying the evidence, it is time to upgrade your infrastructure. You need a partner that understands that traceable AI in healthcare is the only safe AI.
You shouldn't have to choose between fast insights and scientific rigour. With Pienomial, get the velocity of AI with the provenance required for global regulatory defence.
1. Why is evidence traceability described as the "chain of custody" for HTA submissions?
In the context of Health Technology Assessment (HTA), traceability is the digital thread that connects a final value claim back to its specific origin, whether it’s a particular sentence in a PDF or a data point from a clinical trial. Just as supply chains track a drug vial to the patient, evidence traceability ensures that every claim in a Global Value Dossier can be instantly audited. Without this "chain of custody," submissions to bodies like NICE or IQWiG risk rejection because reviewers cannot verify the scientific integrity or the search strategy behind the data.
2. Why are generic Large Language Models (LLMs) considered "scientific novices" despite their ability to write fluently?
Generic LLMs, such as ChatGPT, are built to predict the next plausible word in a sentence rather than to validate clinical truth. When applied to Systematic Literature Reviews (SLRs), they suffer from three fatal flaws: "Zero Provenance" (providing answers without citing specific sources), an "Audit Gap" (making opaque inclusion/exclusion decisions that cannot be defended), and a "Guideline Mismatch" (prioritising conversational fluency over the rigorous standards of PRISMA or GRADE).
3. How does "Traceable AI" solve the "black box" problem found in traditional algorithms?
Traceable AI operates as a "glass box" rather than a "black box." Instead of acting as an oracle that delivers a verdict from the clouds, it functions as a transparent research assistant. It timestamps every decision to include or exclude a record and tags every extracted data point with a direct hyperlink to the source text in the original PDF. This ensures that the evidence is not just generated, but is visually verifiable by human experts.
4. What is the strategic advantage of "audit-ready" evidence synthesis during reimbursement negotiations?
Audit-ready evidence transforms a submission from a static document into a verified assertion of value. During reimbursement review cycles, if a payer challenges a specific cost-effectiveness parameter, teams using audit-ready systems can instantly produce the source lineage. This agility prevents weeks of back-and-forth correspondence, reduces the risk of stalled submissions, and allows teams to defend their value story with confidence and speed.
5. How does the "Traceable AI" framework ensure reproducibility in scientific research?
Science demands that if a search query is run today and again next year, the results must be identical. Generic AI often fails this test due to non-deterministic outputs. Traceable AI ensures reproducibility by creating a permanent, granular log of the search strategy and every screening decision. This allows HTA reviewers or future researchers to replicate the study logic step-by-step, defending the integrity of the review years after it was conducted.
